The expansion brings the number of clinical trials under review by the Type 1 Diabetes Consortium to 74. By increasing this data pool, the institute intends to solidify C-peptide as a reliable drug development tool capable of defining clinically meaningful benefits across various stages of the disease. This initiative follows a pivotal 2025 workshop in which over 400 stakeholders debated how to best preserve beta-cell function.

Simi Ahmed, executive director of the consortium, emphasized that the current challenge lies in quantifying the clinical relevance of beta-cell preservation regarding patient quality of life. The organization serves as a neutral, precompetitive hub where regulators, academics, and pharmaceutical developers align on evidence-generation strategies. By fostering this early dialogue, C-Path seeks to move beyond the current focus on stage 3 diagnoses, creating consistent frameworks that apply to all stages of type 1 diabetes where endogenous beta-cell function remains a viable target for intervention.